Adrian Bot, M.D., Ph.D. is the founding Chief Scientific Officer and Executive Vice President of Research and Development at Capstan Therapeutics, a San Diego-based company developing next generation precision medicines.
Dr. Bot has 26 years of experience in biopharmaceutical industry with focus on discovery and development of targeted therapies in general, and immunotherapies in particular. Previously, he held leadership roles at Kite Pharma and Kite, a Gilead Company, including Chief Scientific Officer and Vice President of Translational Medicine and Discovery Research, respectively.
At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Dr. Bot also served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M.D. in Romania in 1993, his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California.
www.capstantx.com
